Ac El Khoury

Economic burden of hepatitis C-associated diseases in the United States

Summary.  There are approximately 100 drugs in development to treat hepatitis C. Over the next decade, a number of new therapies will become available. A good understanding of the cost of hepatitis C sequelae is important for assessing the value of new treatments. The objective of this study was to assess the economic burden data sources for hepatitis C in the United States. A systematic literature search was conducted to identify studies reporting the costs of hepatitis C sequelae in the United States. Over 400 references were identified, of which 50 were pertinent. The costs were compiled and adjusted to 2010 constant US dollars using the medical component of the consumer price index (CPI). The cost of liver transplants was estimated at

PIN32 Economic Evaluation of Boceprevir for the Treatment of Patients With Genotype 1 Chronic Hepatitis C Virus Infection in Hungary

201 110 (

PIN50 The Clinical Efficacy and Cost-Effectiveness of Boceprevir in Combination with Pegylated Interferon- Alfa and Ribavirin for the Treatment of Genotype 1 Chronic Hepatitis C Patients: A Within Trial Analysis from the Perspective of the Scottish National Health Service (NHS)

178 760–

PIN14 PUBLIC HEATH AND ECONOMIC IMPACT OF ROTAVIRUS VACCINATION IN KOREA

223 460), hepatocellular carcinoma (HCC) at

Treatment Patterns and Healthcare Resource Utilization Among Young Adults with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics

23 755–

The Long-Term Benefits of Ensuring Timely Treatment and Improved Medication Adherence in Early Schizophrenia: A Microsimulation Study

44 200, variceal haemorrhage at

Outcomes Among Medicaid Recipients with Schizophrenia Treated with Once-Every-Three Month Paliperidone Palmitate

25 595, compensated cirrhosis at

PIN48 Cost-Effectiveness of a Pentavalent Human-Bovine Reassortant Rotavirus Vaccine (RV5) in Japan

585–

PIN20 COST-EFFECTIVENESS OF PNEUMOCOCCAL POLYSACCHARIDE VACCINATION IN ADULTS: A SYSTEMATIC REVIEW OF CONCLUSIONS AND ASSUMPTIONS

1110, refractory ascites at

PIN8 BURDEN OF HERPES ZOSTER AND HEALTH AND BUDGET IMPACT OF A VACCINATION PROGRAM

24 755, hepatic encephalopathy at